Century Therapeutics (IPSC) Profit After Tax (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Profit After Tax of -$21.6 million for Q1 2026, down 128.28% year-over-year from $76.5 million in Q1 2025, and down 11.2% quarter-over-quarter from -$19.5 million in Q4 2025.
Century Therapeutics (IPSC) Profit After Tax (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Profit After Tax for 7 consecutive years, with -$21.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 128.28% year-over-year to -$21.6 million; the TTM figure through Mar 2026 stood at -$108.1 million (down 382.49% YoY), while the FY2025 annual figure was -$9.9 million, up 92.19% from the prior year.
- Profit After Tax declined to -$21.6 million in Q1 2026 per IPSC's latest filing, from -$19.5 million in the prior quarter.
- Across five years, Profit After Tax topped out at $76.5 million in Q1 2025 and bottomed at -$38.0 million in Q4 2023.
- Historically, Profit After Tax has averaged -$24.9 million across 5 years, with a median of -$31.2 million in 2024.
- Annual changes were most pronounced in 2025 — Profit After Tax surged 372.76% — and 2026, when it slumped 128.28%.
- Century Therapeutics' Profit After Tax stood at -$30.5 million in 2022, then fell by 24.37% to -$38.0 million in 2023, then grew by 3.89% to -$36.5 million in 2024, then jumped by 46.68% to -$19.5 million in 2025, then dropped by 11.2% to -$21.6 million in 2026.
- Business Quant data shows IPSC's Profit After Tax at -$21.6 million in Q1 2026, -$19.5 million in Q4 2025, and -$34.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | -34.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.66 Mn |
| Mar 31, 2026 | -21.65 Mn |
| Dec 31, 2025 | -19.47 Mn |
| Sep 30, 2025 | -34.42 Mn |
| Jun 30, 2025 | -32.54 Mn |
| Mar 31, 2025 | 76.54 Mn |
| Dec 31, 2024 | -36.51 Mn |
| Sep 30, 2024 | -31.23 Mn |
| Jun 30, 2024 | -31.21 Mn |
| Mar 31, 2024 | -28.06 Mn |
| Dec 31, 2023 | -37.98 Mn |
| Sep 30, 2023 | -32.82 Mn |
| Jun 30, 2023 | -33.29 Mn |
| Mar 31, 2023 | -31.26 Mn |
| Dec 31, 2022 | -30.54 Mn |
| Sep 30, 2022 | -30.92 Mn |
| Jun 30, 2022 | -30.99 Mn |
| Mar 31, 2022 | -37.51 Mn |
| Dec 31, 2021 | -28.78 Mn |
| Sep 30, 2021 | -26.01 Mn |